Shanghai Pharma advances in generics with two approvals

** Shanghai Pharmaceuticals Holding (SSE:601607) has announced significant progress in its generic drug development pipeline. The company's subsidiary, Shanghai Shinyoung Jinzhu Pharmaceutical, received approval for its famotidine injection after passing a generic drug consistency evaluation. Famotidine injection, primarily used for upper gastrointestinal bleeding related to peptic ulcers, represents a market opportunity. The company has spent approximately RMB 4.79 million on R&D for this particular drug.